Cite
HARVARD Citation
Mullins, S. et al. (2019). Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. Journal for immunotherapy of cancer. 7 (1), p. . [Online].